La Société Francophone du Diabète sollicite l’expertise de 3 leaders de l’écosystème du biobanking en France pour accélérer l’identification de nouveaux facteurs associés aux événements cardiovasculaires majeurs (MACE*) chez les patients.
*(major adverse cardiovascular events ou MACE en anglais)
CREAPHARM DEMONSTRATES UNPARALLELED PERFORMANCE OF -80°C NITROGEN TANK TECHNOLOGY
CREAPHARM BIOSERVICES has recently invested in -80°C nitrogen tanks to provide Biotechs and Research key players with a new solution to meet the challenges of ultra-low temperature storage.
A first in France solution for storing high-value biological products at -80°C : CREAPHARM BIOSERVICES unveils its unique offer
CREAPHARM BIOSERVICES announces its investment in -80°C nitrogen tanks to provide the European
ultra-low temperature storage market with unparalleled performance.
